Viking initiated phase 3 trial testing for its oral weight-loss tablet.
Subcutaneous VK2735 achieved up to 22% weight loss in maintenance trials.
Viking raised $575 million, increasing cash holdings to $960 million.
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Viking (NASDAQ:VKTX) announced the initiation of phase 3 registration trials (the final stage of human clinical testing required before regulatory approval) for its oral weight-loss tablet. Advancing oral and injectable formulations of its obesity drug candidate creates multiple commercial opportunities in a growing market. Three takeaways from management's comments highlight the key developments.
Viking initiated its SUNRISE phase 3 registration program to evaluate daily oral tablet doses of VK2735, a dual GLP-1 and GIP receptor agonist that targets hormone pathways regulating appetite. If successful, this pill would offer patients a convenient daily alternative to weekly injections.
And earlier this month, we announced the initiation of the SUNRISE Phase III registration program.
-- Brian Lian, President and Chief Executive Officer
Patients receiving subcutaneous injections (shots administered under the skin) maintained most of their initial weight loss when transitioning from weekly to biweekly or monthly dosing. Less frequent schedules can lower treatment costs and improve long-term patient compliance.
In this study, participants receiving VK2735 successfully maintained the majority of their initial weight loss following the transition to every other week or monthly dosing schedules.
-- Brian Lian, President and Chief Executive Officer
Viking closed stock and convertible note offerings during the quarter, generating $575 million in gross proceeds and expanding total cash to $960 million. The fresh capital funds ongoing phase 3 trials and the preparation for early commercial manufacturing.
These funds substantially increase our financial runway and will support the ongoing development of all programs as well as the company's growing commercial operations and launch plans.
-- Brian Lian, President and Chief Executive Officer
Clinical execution is accelerating across both oral and subcutaneous programs, giving Viking distinct options in a competitive field. The company is building out commercial leadership, expanding supply chain capabilities, and focusing on pricing discipline ahead of potential market entry. Dosing flexibility offers a distinct structural advantage over competitors.
Having the ability to dose weekly, every other week or monthly, I think, imparts flexibility that others cannot offer at this point, and we don't see in the market today.
-- Brian Lian, President and Chief Executive Officer
With four phase 3 trials underway and $960 million on the balance sheet, Viking possesses the resources and clinical scope needed to advance its obesity portfolio toward commercialization.
Viking is now well positioned to advance its ongoing clinical programs and to continue working to deliver a broad portfolio of therapeutic formulation and dosing options to best support a personalized, convenient and sustainable weight loss program for people living with obesity.
-- Brian Lian, President and Chief Executive Officer
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
The Motley Fool has positions in and recommends Viking Therapeutics. The Motley Fool has a disclosure policy.